When the Recommendation Changes
During the second Trump administration, the CDC announced on October 6, 2025, that its immunization schedules would move COVID-19 vaccination to individual-based decision-making. This is also called shared clinical decision-making. The announcement described decisions based on individual characteristics, risk factors, and evidence of potential benefit.
That is a dated policy example, not a statement of what every reader should do today. Its value here is the question it raises: when a recommendation changes, what explanation accompanies it? Did new studies change the estimated benefits or risks? Did officials change how they weighed existing findings? Did the recommendation change for everyone or only for particular groups?
Shared decision-making isn't inherently a retreat from science. It can help apply evidence to an individual. But the phrase alone doesn't establish the quality of the decision. You still need to know what evidence informs the conversation and how it applies to you.
Source:
https://www.cdc.gov/media/releases/2025/cdc-immunization-schedule-adopts-individual-based-decision.html
Funding Decisions Shape Tomorrow's Answers
Research takes time. A long-term study may follow people through changes in health, medication use, and everyday circumstances. Its value includes the continuity of those observations. An interruption can affect what researchers are able to learn later.
The Women's Health Initiative provides a concrete example. On April 21, 2025, its investigators reported that they had been informed that federal Regional Center contracts would end in September. They warned that losing the detailed health-event information collected by those centers would limit future insights into older women's health.
On May 6, the investigators reported official confirmation that the nonrenewal decision had been rescinded and the study could continue. Their announcement said this would allow its work to proceed uninterrupted. This was a reversal within the same administration, showing that policy can change without waiting for an election.
Source:
https://www.whi.org/md/news/whi-funding-announcement
The broader lesson is that a funding decision doesn't establish whether earlier findings were true or false. It changes the resources available to pursue further answers. Before accepting that a project is being ended because its science is weak, look for the stated reason and whether an assessment of scientific quality supports that explanation.
NIH's November 18, 2025, notice on award conditions explicitly included agency priorities among grounds for termination, to the extent authorized by law, and recognized applicable court orders. Scientific performance and agency priorities are therefore distinct considerations in the funding process.
Source:
https://grants.nih.gov/grants/guide/notice-files/NOT-OD-26-009.html
What We Can Know Depends on What We Count
Research findings depend partly on who is included and what information is collected. If a study doesn't identify a particular population, it may be unable to show how that population's experience differs. If follow-up stops, researchers lose opportunities to observe what happens next.
Three situations deserve separate attention: existing information becoming harder to access, future collection ending, and categories being changed so that comparisons become difficult. Each affects knowledge differently. A missing webpage doesn't necessarily mean the underlying dataset was destroyed, and restoring a webpage doesn't establish that future collection will continue.
For example, a long-term study might retain its earlier records after follow-up ends. Researchers could still examine the past, but they couldn't use that discontinued follow-up to learn what happened to participants afterward. The older information remains valuable while the opportunity to answer new questions narrows.
That's why reduced visibility shouldn't be mistaken for a problem disappearing. It may mean our ability to recognize and describe the problem has weakened.